BTG Pactual Asset Management US’s Bio-Rad Laboratories Class A BIO Stock Holding History

BTG Pactual Asset Management US’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$270K	Buy	+920	New	+$261K	0.02%	391

Other funds holding BIO

First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BTG Pactual Asset Management US's BIO Position: Q2 2026 in Review

BTG Pactual Asset Management US opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 920 shares worth $270K. The stake represents 0.02% of the portfolio and ranks #391 among its holdings.

397 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

BTG Pactual Asset Management US held 920 shares of Bio-Rad Laboratories Class A worth $270K as of Q2 2026.
Bio-Rad Laboratories Class A was a new BTG Pactual Asset Management US position in Q2 2026.
Bio-Rad Laboratories Class A made up 0.02% of BTG Pactual Asset Management US's portfolio in Q2 2026, its #391 holding.
397 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on BTG Pactual Asset Management US's 13F filing for Q2 2026, filed 14 Aug 2026.